ALECTINIB, BRIGATINIB, AND LORLATINIB AS FIRST-LINE THERAPIES FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Mudumba, R. [1 ]
Nieva, J. J. [1 ]
Padula, W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE142
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [41] LORLATINIB AS A FIRST-LINE TREATMENT FOR ALK plus ADVANCED NON-SMALL CELL LUNG CANCER: A COSTEFFECTIVENESS ANALYSIS IN SPAIN
    Presa, M.
    Vicente, D.
    Calles, A.
    Salinas-Ortega, L.
    Naik, J.
    Garcia, L. F.
    Soto, J.
    VALUE IN HEALTH, 2022, 25 (12) : S90 - S91
  • [42] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Lifeng Mu
    Benhong Zhou
    Advances in Therapy, 2020, 37 : 968 - 970
  • [43] Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
    Gourzoulidis, George
    Zisimopoulou, Oresteia
    Liavas, Andrianos
    Tzanetakos, Charalampos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (03) : 375 - 385
  • [44] Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
    Luo, Xia
    Zhou, Zhen
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [45] Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong
    Loong, H. H.
    Wong, C. K. H.
    Leung, L. K. S.
    Chan, C. P. K.
    Chang, A.
    Gibbs, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] LORLATINIB AS A FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASEPOSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN GREECE
    Gourzoulidis, G.
    Zisimopoulou, O.
    Liavas, A.
    Tzanetakos, C.
    VALUE IN HEALTH, 2023, 26 (12) : S93 - S93
  • [47] Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis
    Wang, Lida
    Sheng, Zhixin
    Zhang, Junying
    Song, Jiwu
    Teng, Lili
    Liu, Liping
    Li, Qianpeng
    Wang, Baohong
    Li, Bin
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (02) : 87 - 96
  • [48] COST-EFFECTIVENESS OF CRIZOTINIB, CERITINIB, AND ALECTINIB AS FIRST-LINE TREATMENTS FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) METASTATIC NON-SMALL CELL LUNG CANCER
    Xuan, S.
    Ma, J.
    VALUE IN HEALTH, 2018, 21 : S32 - S33
  • [49] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL
    Soares, V
    Orfanos, P.
    Pereira, C.
    VALUE IN HEALTH, 2018, 21 : S38 - S38
  • [50] An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
    Zhou, Yourong
    Yin, Yiming
    Xu, Jiangxin
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Yan, Hao
    Yang, Xiaochun
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (12) : 1361 - 1373
12345